Novartis CEO Sees China Sales Growth In Innovative Drugs, Not Generics
This article was originally published in PharmAsia News
Executive Summary
Novartis CEO Joseph Jimenez is banking on China sales to help carry the Swiss-based firm through a transition period during which it loses patent protection for some of its most successful products